Quantum BioPharma Receives BUY Rating and $45 Price Target from Kingswood Capital Partners

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has received a significant endorsement from Kingswood Capital Partners, which initiated coverage with a BUY rating and a US$45 price target. The biopharmaceutical company, which focuses on developing treatments for neurodegenerative, metabolic, alcohol misuse disorders, gained this positive assessment based on the potential of its lead candidate Lucid-MS.

The valuation methodology employed by Kingswood utilized discounted cash flow analysis, projecting successful Phase 2 and 3 clinical trials for Lucid-MS between 2026 and 2028, followed by a commercial launch in 2029. The research report was led by Kingswood Senior Equity Analyst Karen Sterling, PhD, CFA, and notably, the coverage was prepared independently without compensation from Quantum BioPharma, lending additional credibility to the assessment. Investors can access the full analysis through the official release available at https://ibn.fm/S27oE.

Lucid-MS represents a patented new chemical entity that has demonstrated the ability to prevent and reverse myelin degradation in preclinical models. Myelin degradation is the fundamental pathological process in multiple sclerosis, making this compound particularly promising for addressing the root cause of the disease rather than merely managing symptoms. The drug candidate is being developed through Quantum BioPharma's wholly owned subsidiary, Lucid Psycheceuticals Inc.

Beyond its pharmaceutical developments, Quantum BioPharma maintains additional revenue streams through its ownership stake in Unbuzzd Wellness Inc., where it holds 20.11% ownership as of March 31, 2025. The company also receives royalty payments of 7% of sales from the unbuzzd(TM) product until payments total $250 million, after which the royalty decreases to 3% in perpetuity. Quantum BioPharma retains full rights to develop similar products for pharmaceutical and medical applications.

The company's financial strategy includes maintaining a portfolio of strategic investments through its subsidiary FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. This diversified approach to revenue generation and investment management provides additional stability as the company advances its clinical pipeline. For ongoing updates and news relating to Quantum BioPharma, investors can monitor the company's newsroom at https://ibn.fm/QNTM.

The positive analyst coverage from Kingswood Capital Partners represents a significant milestone for Quantum BioPharma, potentially influencing investor confidence and market perception. For biopharmaceutical companies in development stages, independent analyst endorsements can be crucial for attracting additional investment and partnership opportunities. The $45 price target, substantially above current trading levels, suggests strong growth potential if clinical milestones are achieved as projected.

This development matters to the healthcare investment community as it highlights the growing interest in neurodegenerative disease treatments, particularly those addressing multiple sclerosis. The analyst's confidence in Quantum BioPharma's pipeline could signal broader market recognition of the company's approach to treating neurological conditions through novel mechanisms of action. The successful development of Lucid-MS would address significant unmet medical needs in the multiple sclerosis treatment landscape.